ArticleBMC infectious diseases2026
Development and validation of a prognostic model incorporating the blood urea nitrogen-to-albumin ratio for predicting mortality in methicillin-resistant Staphylococcus aureus bloodstream infection.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with an exceedingly high mortality rate and limited therapeutic options. Early risk stratification is essential to optimize clinical management. This study aimed to evaluate the prognostic value of the blood urea nitrogen-to-albumin ratio (BAR) and to develop a clinically practical model to predict mortality in MRSA bloodstream infections.
methodsA retrospective cohort study that included 410 adult patients with microbiologically confirmed MRSA bloodstream infections hospitalized at a university medical center between January 1, 2020, and December 31, 2024. The primary outcome was 90-day in-hospital mortality. Patients were randomly assigned to a training cohort (n = 308) and a validation cohort (n = 102) for model development and internal validation. Multivariable logistic regression was used to identify independent predictors of mortality, and model performance was assessed in terms of discrimination, calibration, and overall predictive accuracy.
resultsA total of 91 patients (22.2%) experienced 90-day in-hospital all-cause mortality. The mortality group demonstrated significantly higher BAR values [24.74 (14.29–36.00) vs. 5.37 (3.75–12.86); p < 0.001] compared with survivors. Multivariable analysis identified age [adjusted odds ratio (aOR): 1.037, 95% confidence interval (CI): 1.010–1.065; p = 0.007], pulmonary infection (aOR: 2.021, 95% CI: 1.035–3.946; p = 0.039), and BAR (aOR: 1.070, 95% CI: 1.045–1.096; p < 0.001) as independent predictors of mortality. The final BAR-based model demonstrated good discriminative performance, with an AUC of 0.838 in the training cohort and 0.831 in the validation cohort.
conclusionsThe BAR was identified as an independent predictor of mortality in MRSA bacteremia. A practical prediction model with internal validation was developed to support early risk stratification in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.